ITEM 1.     SECURITY AND ISSUER

The class of equity securities to which this statement on Schedule 13D relates is the common stock, par value $0.0001 per share (the “Common Stock”), of Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”). The Company’s principal executive offices are located at Sardinera Beach Building Suite 2, Marginal Costa de Oro, Dorado, Puerto Rico 00646.

ITEM 2.     IDENTITY AND BACKGROUND

This statement on Schedule 13D is being filed by Pentland U.S.A. Inc., the beneficial owner of shares of Common Stock held directly by the Pentland U.S.A. Inc. (the “Reporting Person”).

Pentland U.S.A. Inc. is a Delaware corporation with its principal executive and business office located at 3333 New Hyde Park Road, New Hyde Park, New York 11042. The principal business of the Reporting Person is the distribution of footwear, apparel and related products.

During the past five years, the Reporting Person has not (i) been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or has not (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3.     SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

All purchases of the Common Stock by the Reporting Person were made using working capital. As of the date of the event which required the filing of this Schedule 13-D, the Reporting Person used $750,000 of its working capital to purchase the securities of the Company.

ITEM 4.     PURPOSE OF TRANSACTION

The Reporting Person purchased the securities of the Company for investment purposes only.

ITEM 5.     INTEREST IN SECURITIES OF THE ISSUER

(a)  On January 25, 2006 the Reporting Person purchased 75,000 shares of Series A preferred stock of the Company (the "Preferred Stock") and warrants to purchase 510,600 shares of the Common Stock (the "Warrants"). The Preferred Stock automatically converted into shares of Common Stock on April 25, 2006 upon the filing of a certificate of amendment to the Company’s certificate of incorporation which increased the authorized capital stock (the "Amendment") of the Company. The Warrants became exercisable upon the filing of the Amendment. The agreement pursuant to which the Reporting Person purchased the Preferred Stock and Warrants provided for liquidated damages in the event that the Company failed to file a registration statement in a timely manner. The Company did not file the registration statement in a timely manner, and as a result, the Reporting Person was entitled to 919 shares of Common Stock as liquidated damages on March 30, 2006.

(b)  In connection with the filing of the Amendment, the Reporting Person became the beneficial owner of 1,532,619 shares of Common Stock, comprised of 1,021,100 shares of Common Stock issued upon conversion of the Preferred Stock, 919 shares of Common Stock issued as liquidated damages and warrants to purchase 510,600 shares of Common Stock. The Reporting Person beneficially owns 8.14% of the issued and outstanding securities of the Company. As of April 25, 2006, the Reporting Person had the sole power to vote and dispose of each of the 1,532,619 shares of Common Stock beneficially owned by it.

(c)  Except for the equity issuances described in Item 5(a), during the past sixty days, the Reporting Person did not engage in any transactions involving the Company’s securities reported on herein.

(d)  N/A

(e)  N/A